TY - JOUR
T1 - Hepatitis C-related knowledge, attitudes and perceived risk behaviours among people who inject drugs in Kenya
T2 - A qualitative study
AU - Akiyama, Matthew J.
AU - Muller, Abbe
AU - Huang, Owen
AU - Lizcano, John
AU - Nyakowa, Mercy
AU - Riback, Lindsey
AU - Ross, Jonathan
AU - Bundi, Henry
AU - Kulabi, Euphrasia Shitachi
AU - Mwangi, Ann Muthoni
AU - Musyoki, Helgar
AU - Cherutich, Peter
AU - Kurth, Ann
N1 - Funding Information:
This work was supported by the National Institutes of Health/National Institute on Drug Abuse [grant number R01DA032080, R01DA032080-05S1, K99DA043011, R00DA043011], and a pilot grant from the Albert Einstein College of Medicine Global Health Center. The authors would like to acknowledge several DICs and collaborating partners for their assistance in conducting this research: Teens Watch Centre, Reach Out Centre Trust, Muslim Education and Welfare Association (MEWA), Omari Project, Nairobi Outreach Service Trust (NOSET), Support for Addiction Prevention and Treatment in Africa (SAPTA) and Medecins du Monde (MDM). The authors thank the following deeply for their contributions and support: Peer Case Managers and study participants. The authors are grateful to the NIH/NIDA for study funding (R01DA032080 and R01DA032080-05S1, Kurth and Cherutich, principal investigators; K99DA043011, Akiyama, principal investigator) and NIDA Project Officers Dionne Jones and Raul Mandler for their continuing support.
Funding Information:
This work was supported by the National Institutes of Health/National Institute on Drug Abuse [grant number R01DA032080, R01DA032080-05S1, K99DA043011, R00DA043011], and a pilot grant from the Albert Einstein College of Medicine Global Health Center.
Publisher Copyright:
© 2021 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Despite disproportionately high rates of Hepatitis C (HCV) among people who inject drugs (PWID) in low- and middle-income countries (LMICs), understanding of HCV-related knowledge, attitudes and perceived risk behaviours among this population remains limited. We aimed to elucidate knowledge, attitudes and experiences that could minimise transmission risk and maximise HCV treatment engagement among PWID in Kenya following the integration of HCV screening and education with needle and syringe programmes in drop-in-centres (DICs). We recruited 40 PWID with chronic HCV attending DICs in Nairobi and Coastal Kenya. Semi-structured interviews revealed a general understanding of HCV and awareness of HCV risk behaviours among participants; however, many felt limited control over their transmission risk due to factors such as ‘local doctors’, or individuals who perform a high volume of high-risk injections. Financial barriers, distance to clinic, poor health status and HCV-related stigma were all noted as barriers to HCV treatment. In conclusion, basic knowledge of and motivation for HCV treatment among PWID accessing DICs in Kenya was high; however, structural barriers and stigma complicate access to care. Local education programmes can address knowledge gaps, and behavioural and structural interventions can maximise the impact of HCV care in LMICs.
AB - Despite disproportionately high rates of Hepatitis C (HCV) among people who inject drugs (PWID) in low- and middle-income countries (LMICs), understanding of HCV-related knowledge, attitudes and perceived risk behaviours among this population remains limited. We aimed to elucidate knowledge, attitudes and experiences that could minimise transmission risk and maximise HCV treatment engagement among PWID in Kenya following the integration of HCV screening and education with needle and syringe programmes in drop-in-centres (DICs). We recruited 40 PWID with chronic HCV attending DICs in Nairobi and Coastal Kenya. Semi-structured interviews revealed a general understanding of HCV and awareness of HCV risk behaviours among participants; however, many felt limited control over their transmission risk due to factors such as ‘local doctors’, or individuals who perform a high volume of high-risk injections. Financial barriers, distance to clinic, poor health status and HCV-related stigma were all noted as barriers to HCV treatment. In conclusion, basic knowledge of and motivation for HCV treatment among PWID accessing DICs in Kenya was high; however, structural barriers and stigma complicate access to care. Local education programmes can address knowledge gaps, and behavioural and structural interventions can maximise the impact of HCV care in LMICs.
KW - Hepatitis C virus (HCV)
KW - injection drug use (IDU)
KW - low- and middle-income country (LMIC)
KW - needle syringe programmes (NSP)
KW - people who inject drugs (PWID)
UR - http://www.scopus.com/inward/record.url?scp=85102243973&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85102243973&partnerID=8YFLogxK
U2 - 10.1080/17441692.2021.1896763
DO - 10.1080/17441692.2021.1896763
M3 - Article
C2 - 33689563
AN - SCOPUS:85102243973
SN - 1744-1692
VL - 17
SP - 1016
EP - 1028
JO - Global Public Health
JF - Global Public Health
IS - 6
ER -